Author

J. Chen

Institution: Stemline Therapeutics (United States)

Observed institution: Stemline Therapeutics (United States)

OpenAlex ID: A5010855367

Pf668 Results From Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (sl‐401) in Patients With Intermediate, or High Risk, Relapsed/refractory Myelofibrosis

2019 · N. Pemmaraju, H. Ali, et al. · HemaSphere · 5

Pf672 Results From Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (sl‐401) in Patients With Relapsed/refractory Chronic Myelomonocytic Leukemia (cmml)

2019 · M. Patnaik, H. Ali, et al. · HemaSphere · 1

Works count: 2

Citation count: 6

H-index: 1

I10-index: